paromomycin has been researched along with Neglected Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvar, J; Boelaert, M; Das, P; Mondal, D; Rijal, S; Sundar, S | 1 |
| Alvar, J; Balasegaram, M; Hailu, A; Juma, R; Khalil, EA; Musa, A; Olobo, J; Wasunna, M; Wells, S | 1 |
2 other study(ies) available for paromomycin and Neglected Diseases
| Article | Year |
|---|---|
Eliminating visceral leishmaniasis in South Asia: the road ahead.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Bangladesh; Disease Vectors; Drug Therapy, Combination; Epidemiological Monitoring; Humans; India; International Cooperation; Leishmaniasis, Visceral; Neglected Diseases; Nepal; Paromomycin; Phosphorylcholine; Program Development; Program Evaluation | 2019 |
The Leishmaniasis East Africa Platform (LEAP): strengthening clinical trial capacity in resource-limited countries to deliver new treatments for visceral leishmaniasis.
Topics: Africa, Eastern; Antimony Sodium Gluconate; Antiprotozoal Agents; Biomedical Research; Capacity Building; Cooperative Behavior; Endemic Diseases; Humans; Leishmaniasis, Visceral; Neglected Diseases; Paromomycin | 2016 |